R&G PharmaStudies Co. Ltd. A (301333) - Net Assets
Based on the latest financial reports, R&G PharmaStudies Co. Ltd. A (301333) has net assets worth CN¥1.89 Billion CNY (≈ $276.83 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.31 Billion ≈ $338.06 Million USD) and total liabilities (CN¥418.40 Million ≈ $61.22 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of R&G PharmaStudies Co. Ltd. A to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.89 Billion |
| % of Total Assets | 81.89% |
| Annual Growth Rate | 49.01% |
| 5-Year Change | 444.87% |
| 10-Year Change | N/A |
| Growth Volatility | 98.32 |
R&G PharmaStudies Co. Ltd. A - Net Assets Trend (2019–2024)
This chart illustrates how R&G PharmaStudies Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Also explore R&G PharmaStudies Co. Ltd. A asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for R&G PharmaStudies Co. Ltd. A (2019–2024)
The table below shows the annual net assets of R&G PharmaStudies Co. Ltd. A from 2019 to 2024. For live valuation and market cap data, see 301333 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.84 Billion ≈ $268.68 Million |
+4.64% |
| 2023-12-31 | CN¥1.75 Billion ≈ $256.76 Million |
+10.10% |
| 2022-12-31 | CN¥1.59 Billion ≈ $233.21 Million |
+264.02% |
| 2021-12-31 | CN¥437.81 Million ≈ $64.07 Million |
+29.92% |
| 2020-12-31 | CN¥336.98 Million ≈ $49.31 Million |
+34.93% |
| 2019-12-31 | CN¥249.74 Million ≈ $36.55 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to R&G PharmaStudies Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 310.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥686.76 Million | 37.48% |
| Other Components | CN¥1.15 Billion | 62.52% |
| Total Equity | CN¥1.83 Billion | 100.00% |
R&G PharmaStudies Co. Ltd. A Competitors by Market Cap
The table below lists competitors of R&G PharmaStudies Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Baotou Huazi Industry Co Ltd
SHG:600191
|
$901.20 Million |
|
ABCELLERA BIOLOGICS
F:8QQ
|
$901.24 Million |
|
Asuransi Jiwa Sinarmas Msig PT
JK:LIFE
|
$901.35 Million |
|
Allied Properties Real Estate Investment Trust
TO:AP-UN
|
$901.55 Million |
|
LGI Homes
NASDAQ:LGIH
|
$901.03 Million |
|
Ningbo Runhe High-Tech Materials Co Ltd Class A
SHE:300727
|
$900.97 Million |
|
Jiangsu Baichuan HighTech New Materials Co Ltd
SHE:002455
|
$900.89 Million |
|
Zhejiang China Light & Textile Industrial City Group Co Ltd
SHG:600790
|
$900.86 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in R&G PharmaStudies Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,748,411,556 to 1,832,516,706, a change of 84,105,149 (4.8%).
- Net income of 140,221,110 contributed positively to equity growth.
- Dividend payments of 28,384,500 reduced retained earnings.
- Other factors decreased equity by 27,731,460.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥140.22 Million | +7.65% |
| Dividends Paid | CN¥28.38 Million | -1.55% |
| Other Changes | CN¥-27.73 Million | -1.51% |
| Total Change | CN¥- | 4.81% |
Book Value vs Market Value Analysis
This analysis compares R&G PharmaStudies Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.36x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 12.07x to 3.36x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥5.28 | CN¥63.76 | x |
| 2020-12-31 | CN¥4.48 | CN¥63.76 | x |
| 2021-12-31 | CN¥5.87 | CN¥63.76 | x |
| 2022-12-31 | CN¥16.54 | CN¥63.76 | x |
| 2023-12-31 | CN¥18.21 | CN¥63.76 | x |
| 2024-12-31 | CN¥18.97 | CN¥63.76 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently R&G PharmaStudies Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.65%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 18.85%
- • Asset Turnover: 0.32x
- • Equity Multiplier: 1.27x
- Recent ROE (7.65%) is below the historical average (18.05%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 34.76% | 19.42% | 0.95x | 1.88x | CN¥58.86 Million |
| 2020 | 25.97% | 17.31% | 0.90x | 1.66x | CN¥51.55 Million |
| 2021 | 23.49% | 16.31% | 0.90x | 1.60x | CN¥56.98 Million |
| 2022 | 7.15% | 17.79% | 0.34x | 1.19x | CN¥-45.33 Million |
| 2023 | 9.30% | 22.53% | 0.35x | 1.19x | CN¥-12.31 Million |
| 2024 | 7.65% | 18.85% | 0.32x | 1.27x | CN¥-43.03 Million |
Industry Comparison
This section compares R&G PharmaStudies Co. Ltd. A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $2,109,695,154
- Average return on equity (ROE) among peers: 0.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| R&G PharmaStudies Co. Ltd. A (301333) | CN¥1.89 Billion | 34.76% | 0.22x | $901.11 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $108.47 Million | -73.31% | 2.66x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.66 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $-14.51 Million | 0.00% | 0.00x | $443.33 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $660.31 Million | 2.17% | 0.39x | $438.41 Million |
| Chengzhi Shareholding Co Ltd (000990) | $930.16 Million | 5.16% | 0.80x | $2.24 Billion |
| Hualan Biological EngineeringInc (002007) | $3.88 Billion | 15.17% | 0.04x | $3.86 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $269.70 Million | 9.75% | 0.10x | $1.19 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $12.48 Billion | 6.70% | 0.16x | $5.40 Billion |
| Baolingbao Biology Co Ltd (002286) | $703.11 Million | 6.09% | 0.47x | $572.48 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $1.55 Billion | 15.33% | 0.16x | $1.90 Billion |
About R&G PharmaStudies Co. Ltd. A
R&G PharmaStudies Co., Ltd. operates as a clinical trial outsourcing service provider in China and internationally. It provides drug clinical research and development integrated services. The company's services include clinical trial operation, clinical trial site management, biological sample testing, data management and statistical analysis, clinical trial consulting, and clinical pharmacology … Read more